RNA Scissors offer New Hope for Progeria and Age-Related Diseases

Breakthrough RNA-Targeting Therapy reverses Progeria Symptoms in Mice, Hints at Broader Anti-Aging Potential

Seoul, South Korea – Scientists have developed a novel RNA-targeting therapy that has shown remarkable success in reversing the debilitating symptoms of Hutchinson-Gilford progeria Syndrome (HGPS) in a mouse model. The innovative approach, which utilizes a modified CRISPR system known as RfxCas13d, offers a safer and potentially reversible alternative to traditional gene-editing techniques, opening doors for treating a wide range of genetic disorders and age-related diseases.

A Precision Strike Against Progeria

Hutchinson-Gilford Progeria Syndrome is a rare, fatal genetic disorder characterized by the rapid acceleration of aging in children. it is indeed caused by a mutation in the LMNA gene, leading to the production of a toxic protein called progerin. This aberrant protein accumulates in cells, causing severe damage and the premature aging symptoms associated with the disease.

Unlike gene-editing methods like CRISPR-Cas9 that permanently alter DNA, this new RNA-targeting strategy precisely targets and modifies the messenger RNA (mRNA) produced from the mutated gene. This means it only affects the progerin protein itself, leaving the underlying DNA intact. This crucial distinction offers a considerably higher safety profile and the potential for reversibility if any unintended effects arise.

Promising Results in Preclinical Trials

When applied to a mouse model engineered to carry the progeria mutation, the RNA-targeting therapy demonstrated a profound reversal of hallmark disease symptoms.Treated mice exhibited significant improvements, including:

Restored Physical Health: Reversal of hair loss, skin atrophy, and spinal curvature.
Improved Mobility: Enhanced physical function and movement.
Organ Function: Restoration of body weight and reproductive organ health.
Cardiovascular and Muscular Benefits: Improved heart and muscle health, bringing them closer to the condition of healthy control mice.

Beyond Progeria: A Platform for Aging and Disease

The implications of this research extend far beyond HGPS. The study’s findings suggest a powerful new avenue for precisely regulating aging processes. Researchers observed that progerin levels naturally increase in aged human skin cells, and the request of the RNA-targeting tool helped to delay certain visible signs of aging in these cells.

Dr. Sun-Uk Kim, the lead researcher from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), expressed optimism about the technology’s broad applicability. “This technology is not only applicable to Hutchinson-Gilford Progeria Syndrome but also holds therapeutic potential for over 15% of genetic disorders caused by RNA editing errors,” he stated. “We expect this to evolve into a versatile platform technology with broad applicability to age-related diseases, cancer, and neurodegenerative disorders.”

A Collaborative Effort Driving Innovation

This groundbreaking research was supported by several key programs, including the Big Issue Group Program (KRIBB Research Initiative Program) and the Global TOP Program funded by the National Research Council of science & Technology (NST). Further support came from the Excellent Young Researcher Program under the Basic Science Research Program of the Ministry of Science and ICT (MSIT), and the Core Technology Progress Program for the Bio-Industry of the Ministry of Trade, Industry and Energy (MOTIE).

the study, titled “Precise progein targeting using RfxCas13d: A therapeutic avenue for Hutchinson-Gilford Progeria Syndrome,” was published online on June 14, 2025, in the esteemed international journal molecular Therapy (Impact Factor: 12.0). The research was led by Dr. Sun-Uk Kim and Young-Ho Park as corresponding authors, with Dr. Unbin Chae, Hae-jun yang, and Hanseop Kim serving as first authors, all from KRIBB.

The Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a leading national research institute in South Korea, committed to advancing scientific knowledge in biotechnology and life sciences. Established in 1985, KRIBB plays a crucial role in driving innovation through its research in molecular biology, genomics, bioinformatics, synthetic biology, and aging-related studies, fostering collaborations both domestically and internationally.

*This material from the originating institution/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s). View in full